A pivotal clinical trial has been terminated prematurely, marking a significant setback for Pfizer and BioNTech. Their large U.S. study for the COVID-19 vaccine Comirnaty has been halted, not due to safety concerns, but because of an inability to enroll enough participants. The implications of this decision extend far beyond the closure of a single research program.
Financial Backdrop and Strategic Pivot
This development underscores a trend already reflected in BioNTech’s financial forecasts: its COVID-related business is contracting. The company anticipates a revenue decline of approximately 25% for 2026, projecting sales between €2.0 and €2.3 billion. This follows a modest 4% growth expected for 2025. The recently concluded fiscal year also resulted in a net loss of €1.14 billion.
Despite these challenges, BioNTech’s balance sheet remains robust. The firm ended 2025 with a liquidity reserve of roughly €17.2 billion, providing substantial financial flexibility to fund its strategic transition. This shift is centered on its oncology pipeline, which features candidates such as the anti-CTLA-4 antibody Gotistobart, the antibody-drug conjugate BNT323, and the bispecific molecule BNT327. However, the company does not yet forecast commercial revenue from this segment for 2026.
The Anatomy of a Trial Failure
The study was designed for healthy adults aged 50 to 64, targeting enrollment of 25,000 to 30,000 individuals. That goal was never met. A milder-than-anticipated COVID season was one factor. Another was the stringent inclusion criteria set by the U.S. Food and Drug Administration (FDA), which disqualified potential participants with chronic conditions like hypertension or diabetes. According to a representative from a contract research organization involved, over 80% of interested candidates failed the initial screening.
Should investors sell immediately? Or is it worth buying BioNTech?
Patient enrollment was officially closed on March 6, and monitoring for COVID-19 cases was stopped on April 3. The regulatory consequences are significant. Currently, no COVID-19 vaccine, including Comirnaty, holds full FDA approval for healthy adults in the 50-64 age bracket. Without the data from this abandoned trial, securing such an approval appears unlikely in the near term. Former FDA chief scientist Jesse Goodman stated plainly that the lack of data probably means no presentation before the advisory committee—and without that presentation, no specific authorization.
Upcoming Shareholder Meeting and Pipeline Milestones
BioNTech has scheduled its Annual General Meeting for May 15, 2026, to be held virtually. Key agenda items include a proposal to expand the Supervisory Board from six to eight members, with the election of two new specialists in oncology and clinical development. Shareholders will also vote on a new capital authorization of up to €129.5 million, equivalent to 50% of the current share capital. The entire retained profit for 2025, approximately €6.9 billion, is to be carried forward.
Concurrently, 2026 is set to deliver several key clinical data readouts from late-stage trials within BioNTech’s oncology portfolio. These results will be a critical test, indicating whether the company’s strategic transformation can move beyond promise to tangible success.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from April 7 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 7.
BioNTech: Buy or sell? Read more here...
